Tryptophan-containing
isoprenoid indole alkaloid natural products
are well known for their intricate structural architectures and significant
biological activities. Nature employs dimethylallyl tryptophan synthases
(DMATSs) or aromatic indole prenyltransferases (iPTs) to catalyze
regio- and stereoselective prenylation of
l
-Trp. Regioselective
synthetic routes that isoprenylate
cyclo
-Trp-Trp
in a 2,5-diketopiperazine (DKP) core, in a desymmetrizing manner,
are nonexistent and are highly desirable. Herein, we present an elaborate
report on Brønsted acid-promoted regioselective tryptophan isoprenylation
strategy, applicable to both the monomeric amino acid and its dimeric
l
-Trp DKP. This report outlines a method that regio- and stereoselectively
increases sp
3
centers of a privileged bioactive core.
We report on conditions involving screening of Brønsted acids,
their conjugate base as salt, solvent, temperature, and various substrates
with diverse side chains. Furthermore, we extensively delineate effects
on regio- and stereoselection of isoprenylation and their stereochemical
confirmation
via
NMR experiments. Regioselectively,
the C3-position undergoes
normal
-isoprenylation or
benzylation and forms
exo
-ring-fused pyrroloindolines
selectively. Through appropriate prenyl group migrations, we report
access to the bioactive tryprostatin alkaloids, and by C3-
normal
-farnesylation, we access anticancer drimentines as
direct targets of this method. The optimized strategy affords
iso
-tryprostatin B-type products and predrimentine C with
58 and 55% yields, respectively. The current work has several similarities
to biosynthesis, such as—reactions can be performed on unprotected
substrates, conditions that enable Brønsted acid promotion, and
they are easy to perform under ambient conditions, without the need
for stoichiometric levels of any transition metal or expensive ligands.
An expedient and straightforward protocol is developed for the synthesis of highly enantiopure synthesis of γ‐butyrolactones. For the first time, one pot enantioselective organocatalytic multicomponent reaction (OMCR) is explored to construct functionalized butyrolactones without the use of pre‐functionalized substrates and expensive transition metals. The protocol is proved to be reproducible on a gram scale. Density functional theory (DFT) calculations strongly support the mechanism and were in close agreement with the observed high stereoselectivity.magnified image
The 2,5-diketopiperazines are a prominent class of bioactive molecules. The nocardioazines are actinomycete natural products that feature a pyrroloindoline diketopiperazine scaffold composed of two D-tryptophan residues functionalized by N- and C-methylation, prenylation, and diannulation. Here we identify and characterize the nocardioazine B biosynthetic pathway from marine Nocardiopsis sp. CMB-M0232 by using heterologous biotransformations, in vitro biochemical assays, and macromolecular modeling. Assembly of the cyclo-L-Trp-L-Trp diketopiperazine precursor is catalyzed by a cyclodipeptide synthase. A separate genomic locus encodes tailoring of this precursor and includes an aspartate/glutamate racemase homolog as an unusual D/L isomerase acting upon diketopiperazine substrates, a phytoene synthase-like prenyltransferase as the catalyst of indole alkaloid diketopiperazine prenylation, and a rare dual function methyltransferase as the catalyst of both N- and C-methylation as the final steps of nocardioazine B biosynthesis. The biosynthetic paradigms revealed herein showcase Nature’s molecular ingenuity and lay the foundation for diketopiperazine diversification via biocatalytic approaches.
Nocardioazines A and B are prenylated, bioactive pyrroloindoline natural products, isolated from Nocardiopsis, with a desymmetrized cyclo-D-Trp-D-Trp DKP core. Based on our deeper biosynthetic understanding, a biomimetic total synthesis of (+)-nocardioazine B is accomplished in merely seven steps and 23.2% overall yield. This pathway accesses regio-and stereoselectively C3-isoprenylated analogs of (+)-nocardioazine B, using the same number of steps and in similar efficiency. The successful strategy mandated that the biomimetic C3-prenylation step be executed early. The use of an unprotected carboxylic acid of Trp led to high diastereoselectivity toward formation of key intermediates exo-12a, exo-12b, and exo-12c (>19:1). Evidence shows that N1methylation causes the prenylation reaction to bifurcate away to result in a C2-normal-prenylated isomer. Nocardioazine A, possessing an isoprenoidal-epoxide bridge, inhibits P-glycoprotein (P-gp)-mediated membrane efflux, in multidrug-resistant mammalian colon cancer cells. As several P-gp inhibitors have failed due to their toxicity effects, endogenous amino-acid-derived noncytotoxic inhibitors (from the nocardioazine core) are worthy leads toward a rejuvenated strategy against resistant carcinomas. This total synthesis provides direct access to Trp-derived isoprenylated DKP natural products and their derivatives.
An enantioselective organocatalytic multicomponent reaction of aldehydes, ketones, and Meldrum's acid has been developed. A cinchona-based primary amine (1 mol %) catalyses the multicomponent reaction via the formation of the Knoevenagel product and a chiral enamine to form enantiopure δ-keto Meldrum's acids in a tandem catalytic pathway. An adverse effect of higher catalyst loading and longer reaction time on enantioselectivity was studied. This mild protocol provides an easy access to enantiopure carboxylic acids, esters and amides and the method is scalable on a gram quantity. DFT calculations were carried out on the proposed reaction mechanism and they were in close agreement with the experimental results.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.